Astellas Pharma Inc: Diabetes Mellitus trials

The registry lists 39 Diabetes Mellitus studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 7Phase 2 11Phase 3 16Phase 4 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With AlbuminuriaTerminatedNCT03118713Phase 4
• A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes MellitusCompletedNCT02897219Phase 3
• Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin TherapyCompletedNCT02847091Phase 4
• A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on MetforminCompletedNCT02794792Phase 3
• Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus PatientsTerminatedNCT02786979Phase 4
• Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes MellitusCompletedNCT02529449Phase 2
• Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes PatientsCompletedNCT02479399
• A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02452632Phase 3
• A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT02358096Phase 2
• A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)CompletedNCT02302079Phase 2
• The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes PatientsCompletedNCT02297620
• Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02291874Phase 4
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney DiseaseCompletedNCT02218099Phase 1/2
• A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes MellitusCompletedNCT02175784Phase 4
• A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes PatientsCompletedNCT01672762Phase 3
• A Phase 1 Study to Investigate the Mechanism of Action of IpragliflozinCompletedNCT01611363Phase 1
• A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusTerminatedNCT01514838Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes PatientsCompletedNCT01505426Phase 3
• A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsCompletedNCT01316107Phase 3
• A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal ImpairmentCompletedNCT01316094Phase 3
• Drug to Drug Interaction Study With ASP1941 and MetforminCompletedNCT01302145Phase 1
• Renal Impairment Study With ASP1941CompletedNCT01302028Phase 1
• Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941CompletedNCT01288898Phase 1
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242228Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic PatientsCompletedNCT01242215Phase 3
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242202Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsCompletedNCT01225081Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic PatientsCompletedNCT01135433Phase 3
• A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes MellitusCompletedNCT01117584Phase 2
• A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal ImpairmentCompletedNCT01097681Phase 1
• A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes MellitusCompletedNCT01071850Phase 2
• A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes PatientsCompletedNCT01057628Phase 3
• A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic PatientsCompletedNCT01054092Phase 3
• A Study of ASP1941 in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01023945Phase 1
• A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.CompletedNCT00790660Phase 2
• A Study of ASP1941 in Participants With Type 2 Diabetes MellitusCompletedNCT00621868Phase 2
• A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus SubjectsCompletedNCT00454233Phase 2
• Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic PatientsCompletedNCT00189774Phase 2/3
• Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a SulfonylureaCompletedNCT00036192Phase 2